Stock listing
Dusseldorf:UU8 Neurogene Inc. Aktie
German listing (Dusseldorf) of Neurogene Inc. · home listing NASDAQ:NGNE
Follow Neurogene Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:NGNE
$22.15 USD -0.99 (-4.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:NGNE
- Day range
- $22.03 – $22.90 USDNov 20, 2026
- Volume
- 178,264 sharesNov 20, 2026
- Market cap
- $458.5M USDAt the close on Nov 20, 2026 · price × 20.70M shares outstanding
- 52-week range
- $15.93 – $43.66 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $9.05M USDMedian day 232,132 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NGNE · Home | $22.15 USD | -0.99 (-4.3%) | 178,264 | $22.27 | $22.90 | $22.03 | $23.14 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NGNE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $22.15 | -0.99 | -4.3% | $22.27 | $22.90 | $22.03 | 178,264 | |
| $23.14 | +0.04 | +0.2% | $22.97 | $23.74 | $22.28 | 248,968 | |
| $23.10 | -0.20 | -0.9% | $23.38 | $23.38 | $22.21 | 278,142 | |
| $23.30 | -0.63 | -2.6% | $23.95 | $24.65 | $23.18 | 244,301 | |
| $23.93 | +0.03 | +0.1% | $23.96 | $24.50 | $23.29 | 193,616 | |
| $23.90 | -1.20 | -4.8% | $24.77 | $24.99 | $22.70 | 237,849 | |
| $25.10 | -0.18 | -0.7% | $25.53 | $26.94 | $24.83 | 199,762 | |
| $25.28 | -0.72 | -2.8% | $25.22 | $26.35 | $24.22 | 344,519 | |
| $26.00 | +0.69 | +2.7% | $26.26 | $26.75 | $24.45 | 442,080 | |
| $25.31 | -0.34 | -1.3% | $26.33 | $27.26 | $24.68 | 324,879 | |
| $25.65 | -1.93 | -7.0% | $27.61 | $28.50 | $25.57 | 380,728 | |
| $27.58 | +0.91 | +3.4% | $27.79 | $28.10 | $26.15 | 208,910 | |
| $26.67 | +0.06 | +0.2% | $27.11 | $28.59 | $26.43 | 186,619 | |
| $26.61 | -0.94 | -3.4% | $27.85 | $29.23 | $26.47 | 173,618 | |
| $27.55 | -1.27 | -4.4% | $28.53 | $29.38 | $26.77 | 249,044 | |
| $28.82 | -1.60 | -5.3% | $30.50 | $32.09 | $28.50 | 309,992 | |
| $30.42 | +3.43 | +12.7% | $26.99 | $31.14 | $25.81 | 646,309 | |
| $26.99 | +3.45 | +14.7% | $23.71 | $27.23 | $23.26 | 484,939 | |
| $23.54 | -0.01 | 0.0% | $23.75 | $24.43 | $23.32 | 123,200 | |
| $23.55 | -0.73 | -3.0% | $24.11 | $24.11 | $23.08 | 124,512 | |
| $24.28 | -1.80 | -6.9% | $25.74 | $26.38 | $24.09 | 212,380 | |
| $26.08 | +0.68 | +2.7% | $25.52 | $26.94 | $25.11 | 588,807 | |
| $25.40 | +1.23 | +5.1% | $24.20 | $25.84 | $23.80 | 205,897 | |
| $24.17 | +0.92 | +4.0% | $23.26 | $24.39 | $22.78 | 240,177 | |
| $23.25 | -0.70 | -2.9% | $24.00 | $24.27 | $23.00 | 571,531 | |
| $23.95 | +1.77 | +8.0% | $22.35 | $24.41 | $22.35 | 587,986 | |
| $22.18 | +0.62 | +2.9% | $21.05 | $22.50 | $21.05 | 522,546 | |
| $21.56 | -2.88 | -11.8% | $24.32 | $25.17 | $21.40 | 442,253 | |
| $24.44 | -1.96 | -7.4% | $26.13 | $27.15 | $24.19 | 388,006 | |
| $26.40 | -0.10 | -0.4% | $28.90 | $29.63 | $26.01 | 465,903 | |
| $26.50 | +0.63 | +2.4% | $28.00 | $28.97 | $26.24 | 509,475 | |
| $25.87 | +0.42 | +1.7% | $25.14 | $26.01 | $25.01 | 114,069 | |
| $25.45 | -1.02 | -3.9% | $26.63 | $26.74 | $25.04 | 121,651 | |
| $26.47 | +0.82 | +3.2% | $25.71 | $26.76 | $24.87 | 211,773 | |
| $25.65 | -0.90 | -3.4% | $26.95 | $26.95 | $24.86 | 401,641 | |
| $26.55 | -1.27 | -4.6% | $27.68 | $28.54 | $26.44 | 182,600 | |
| $27.82 | -0.57 | -2.0% | $28.52 | $28.62 | $27.40 | 160,126 | |
| $28.39 | -0.09 | -0.3% | $28.50 | $29.16 | $28.05 | 176,742 | |
| $28.48 | +0.17 | +0.6% | $28.20 | $28.82 | $27.64 | 176,387 | |
| $28.31 | -2.94 | -9.4% | $31.31 | $31.31 | $28.23 | 200,108 | |
| $31.25 | +0.32 | +1.0% | $30.85 | $31.78 | $30.43 | 374,883 | |
| $30.93 | -2.67 | -7.9% | $33.49 | $33.53 | $30.09 | 276,187 | |
| $33.60 | +1.03 | +3.2% | $32.94 | $34.45 | $32.79 | 1,223,247 | |
| $32.57 | +0.48 | +1.5% | $32.09 | $32.84 | $31.21 | 325,534 | |
| $32.09 | -0.32 | -1.0% | $32.49 | $33.15 | $31.86 | 1,388,879 | |
| $32.41 | -2.26 | -6.5% | $35.36 | $35.64 | $32.04 | 171,608 | |
| $34.67 | +0.98 | +2.9% | $34.04 | $34.86 | $33.53 | 232,132 | |
| $33.69 | -1.52 | -4.3% | $35.04 | $35.04 | $33.46 | 147,611 | |
| $35.21 | -0.27 | -0.8% | $35.92 | $36.28 | $34.70 | 194,666 | |
| $35.48 | -0.64 | -1.8% | $36.50 | $37.64 | $35.38 | 181,388 | |
| $36.12 | -1.76 | -4.6% | $37.51 | $38.25 | $36.07 | 177,111 | |
| $37.88 | -0.25 | -0.7% | $38.04 | $40.42 | $37.86 | 193,179 | |
| $38.13 | -0.47 | -1.2% | $37.79 | $38.75 | $36.68 | 228,474 | |
| $38.60 | +0.99 | +2.6% | $37.25 | $39.38 | $36.56 | 205,633 | |
| $37.61 | -0.75 | -2.0% | $38.74 | $39.19 | $36.65 | 255,221 | |
| $38.36 | +0.49 | +1.3% | $37.97 | $39.78 | $36.86 | 252,961 | |
| $37.87 | +1.63 | +4.5% | $35.80 | $38.21 | $35.31 | 134,478 | |
| $36.24 | -0.34 | -0.9% | $36.13 | $36.64 | $35.26 | 120,388 | |
| $36.58 | -1.28 | -3.4% | $37.68 | $38.56 | $36.32 | 132,795 | |
| $37.86 | -0.55 | -1.4% | $38.50 | $39.81 | $37.39 | 149,922 | |
| $38.41 | -2.43 | -6.0% | $40.74 | $41.77 | $38.27 | 180,171 | |
| $40.84 | +1.20 | +3.0% | $40.09 | $42.01 | $39.13 | 504,339 | |
| $39.64 | +1.01 | +2.6% | $38.64 | $40.82 | $37.50 | 439,100 | |
| $38.63 | +0.64 | +1.7% | $38.41 | $39.44 | $37.54 | 346,580 | |
| $37.99 | -1.44 | -3.7% | $38.55 | $38.60 | $36.78 | 124,693 |
Splits
2 splits since 2023 · NASDAQ:NGNE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation | |
| 1-for-5 | Consolidation |
- Ticker
- Dusseldorf:UU8
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 9, 2026
Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
Latest deck · Nov 9, 2026
Investor Presentation (November 2026)
Investor deck · 38 slides
Latest news
Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
Nov 9, 2026
Closed $26.00 (+2.7%) on Nov 9, 2026
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2026
Closed $25.31 (-1.3%) on Nov 6, 2026
Neurogene to Participate in Upcoming Investor Conferences
Nov 3, 2026
Closed $26.67 (+0.2%) on Nov 3, 2026
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Oct 27, 2026
Closed $26.99 (+14.7%) on Oct 27, 2026
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Oct 20, 2026
Closed $25.40 (+5.1%) on Oct 20, 2026
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 5, 2026
Closed $25.45 (-3.9%) on Oct 6, 2026
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026
Closed $38.13 (-1.2%) on Sep 8, 2026
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Aug 11, 2026
Closed $35.80 (-2.1%) on Aug 11, 2026
Neurogene Inc. Announces Pricing of $125 Million Public Offering
Jul 1, 2026
Closed $33.88 (+7.7%) on Jul 1, 2026
Neurogene Inc. Announces Proposed Public Offering
Jun 30, 2026
Closed $33.88 (+7.7%) on Jul 1, 2026
Neurogene Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 104 in all · newest Nov 9, 2026 · oldest 2020
- Calls
- 2 calls with a replay · 2 with a transcript · latest Aug 9, 2022
- Decks
- 26 decks · latest Nov 9, 2026
Where Neurogene Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NGNE · Home listing | NASDAQ | United States | USD |
| LS Exchange:A3EX79 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3EX79 | Lang & Schwarz | Germany | EUR |
| BOATS:NGNE | BOATS | United States | USD |
| Frankfurt:UU8 | Frankfurt | Germany | EUR |
| Dusseldorf:UU8 · This page | Dusseldorf | Germany | EUR |
| Tradegate:UU8 | Tradegate | Germany | EUR |
| Stuttgart:UU8 | Stuttgart | Germany | EUR |
Valuation
Price/book 1.3× against a median of 2.6×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $106.4M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Neurogene Inc. · NASDAQ:NGNE | US$458.5M | US$106.4M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.47 |
| Sana Biotechnology, Inc. · NASDAQ:SANA | US$476.4M | US$408.5M | n/a | n/a | n/a | 2.6× | n/a | 0.3× | 2.29 |
| Regenxbio Inc. · NASDAQ:RGNX | US$473.4M | US$289.0M | n/a | 1.9× | n/a | 3.2× | −113.9% | 0.5× | 1.60 |
| Monopar Therapeutics Inc. · NASDAQ:MNPR | US$467.6M | US$362.8M | n/a | n/a | n/a | 3.7× | n/a | 0.0× | 1.18 |
| BlossomHill Therapeutics, Inc. · NASDAQ:BLSM | US$461.2M | US$259.4M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | n/a |
| Assembly Biosciences, Inc. · NASDAQ:ASMB | US$454.4M | US$142.3M | n/a | 2.1× | n/a | 1.5× | −16.6% | 0.0× | 1.00 |
| Shattuck Labs, Inc. · NASDAQ:STTK | US$454.2M | US$260.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.10 |
| G2GBIO, Inc. · KRX:456160 | US$449.3M | US$289.1M | n/a | 176× | n/a | 4.3× | −793.7% | 0.0× | n/a |
| DiaMedica Therapeutics Inc. · NASDAQ:DMAC | US$445.1M | US$410.4M | n/a | n/a | n/a | 15.5× | n/a | 0.0× | 1.67 |
| CytomX Therapeutics, Inc. · NASDAQ:CTMX | US$442.5M | US$98.96M | n/a | 7.0× | n/a | 1.6× | −609.0% | 0.0× | 1.21 |
| Hansa Biopharma AB · OMXSTO:HNSA | US$441.3M | US$488.5M | n/a | 26.3× | n/a | n/a | −406.5% | n/a | n/a |
| Median of the others | US$454.3M | US$289.1M | 7.0× | 2.6× | −406.5% | 0.0× | 1.21 |
Forecasts
9 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 77.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.98 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Rachel McMinn | Founder and Chief Executive Officer |
| Christine Mikail | President and Chief Financial Officer |
| Keith Woods | Chief Operating Officer |
| Donna M. Cochener | Senior Vice President and General Counsel |
| Lina Li | Executive Director, Investor Relations |
| Mike Devine | Executive Director, Corporate Communications |
| Andrew Mulberg | Senior Vice President, Regulatory Affairs, Quality Assurance, and Quality Control |
| Arvind Sreedharan | Senior Vice President, Business Operations |
| Ricardo Jimenez | Senior Vice President, Technical Operations |
| Christy Shafer | Chief Commercial Officer |
| Julie Jordan | Chief Medical Officer |
| Sarah B. Noonberg | Chief Medical Officer |
| Stuart Cobb | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Lina Li | Executive Director, Investor Relations |
| Mike Devine | Executive Director, Corporate Communications |
Events
Calls
| Call | When | Status |
|---|---|---|
| Neoleukin Therapeutics, Inc. (NLTX) Q2 2022 Earnings Call | Tue, Aug 09, 2022 · 4:30 PM ET | Replay |
| Neoleukin Therapeutics, Inc. (NLTX) Q4 2021 Earnings Call | Tue, Mar 01, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | −2.8% |
| Q2 2026 | Aug 11, 2026 · After close | +3.3% |
| Q1 2026 | May 13, 2026 | −0.9% |
| Q4 2025 | Mar 24, 2026 · After close | +5.4% |
| Q3 2025 | Nov 13, 2025 · After close | −14.0% |
| Q2 2025 | Aug 11, 2025 · After close | −5.5% |
| Q1 2025 | May 8, 2025 · Before open | +8.2% |
| Q4 2024 | Mar 24, 2025 · After close | +1.7% |
| Q3 2024 | Nov 18, 2024 · After close | −13.1% |
| Q2 2024 | Aug 9, 2024 · Before open | −2.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · After close | −5.7% |
| Q4 2023 | Mar 18, 2024 · After close | +20.0% |
| Q3 2023 | Nov 14, 2023 | +2.7% |
| Q2 2023 | Aug 16, 2023 | +8.1% |
| Q1 2023 | May 10, 2023 | −0.9% |
| Q4 2022 | Mar 16, 2023 | +4.6% |
| Q3 2022 | Nov 14, 2022 | −21.4% |
| Q2 2022 | Aug 9, 2022 | −7.2% |
| Q1 2022 | May 9, 2022 | −6.5% |
| Q4 2021 | Mar 1, 2022 | +5.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 38 slides | Nov 9, 2026 |
| Investor Presentation (August 2026) | Investor deck | 37 slides | August 2026 |
| Technical Presentation (June 2026) | Technical | 38 slides | Jun 29, 2026 |
| Investor Presentation (June 2026) | Investor deck | 33 slides | Jun 8, 2026 |
| Investor Presentation (May 2026) | Investor deck | 33 slides | May 12, 2026 |
| Investor Presentation (March 2026) | Investor deck | 33 slides | Mar 24, 2026 |
| Investor Presentation (January 2026) | Investor deck | 28 slides | Jan 12, 2026 |
| Investor Presentation (November 2025) | Investor deck | 35 slides | Nov 13, 2025 |
| Corporate Update (November 2025) | Corporate update | 22 slides | Nov 12, 2025 |
| Investor Presentation (November 2025) | Investor deck | 36 slides | Nov 6, 2025 |
All 26 decks
Financings
| Raise | Date |
|---|---|
| Public offering of shares Closed: US$144M raised | Aug 11, 2026 |
| Public offering of shares of common stock and pre-funded warrants Update: about US$125M · US$30 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead), William Blair (co-lead) Use of proceeds: Fund clinical development and pre-commercial activities for NGN-401, working capital and general corporate purposes | Jul 1, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as AQUINOX PHARMACEUTICALS, INC. Priced at US$11.00 a share on Mar 6, 2014.
- Price
- US$11.00 a share
- Shares offered
- 4,200,000 shares of common stock
- Offering size
- US$46.2 million
- Underwriters' option
- Up to 630,000 more shares
- Underwriters
- Jefferies, Cowen and Company, Canaccord Genuity · In the order on the cover
- Shares delivered
- On or about Mar 12, 2014
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Nov 18, 2013 |
| Filed publicly | Jan 28, 2014 |
| Amended once | Feb 28, 2014 |
| Shares registered with an exchange | Mar 3, 2014 |
| Declared effective by the SEC | Mar 6, 2014 |
| Final prospectus, with the price | Mar 7, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 7, 2014 |
| EFFECT · Notice that a registration is effective | Mar 6, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Mar 4, 2014 |
| CORRESP · Letter to the SEC | Mar 4, 2014 |
| CORRESP · Letter to the SEC | Mar 4, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 3, 2014 |
| S-1/A · Registration statement, amended | Feb 28, 2014 |
| CORRESP · Letter to the SEC | Jan 28, 2014 |
| S-1 · Registration statement | Jan 28, 2014 |
| UPLOAD · Letter from the SEC | Jan 9, 2014 |
All 14 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Dec 24, 2013 |
| DRS/A · Draft registration statement, amended | Dec 24, 2013 |
| UPLOAD · Letter from the SEC | Dec 19, 2013 |
| DRS · Draft registration statement | Nov 18, 2013 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 7, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 925.0K | 0 | 0 | 0 | 25.0M | ||||
| Cost of revenue | 3.19M | 3.25M | 3.26M | 3.20M | 42.3M | 1.82M | 340.0K | |||
| Gross profit | -3.19M | -2.32M | -3.26M | -3.20M | -42.3M | -1.82M | -340.0K | 25.0M | ||
| Research and development | 75.0M | 60.9M | 44.4M | 47.5M | 39.2M | 24.3M | 4.42M | 41.8M | 36.3M | 28.4M |
| Selling, general and administrative | 28.3M | 22.6M | 11.2M | 9.01M | 8.27M | |||||
| Operating income | -103.3M | -82.6M | -55.6M | -56.5M | -60.7M | -33.7M | -71.0M | -32.6M | -51.1M | -37.6M |
| Depreciation and amortization | 3.04M | 3.19M | 3.26M | 3.20M | 1.31M | 785.0K | 340.0K | 289.0K | 360.0K | 1 |
| EBITDA | -100.3M | -79.4M | -52.3M | -53.3M | -59.4M | -32.9M | -70.6M | -32.3M | -50.8M | -37.6M |
| Interest expense | 5.00K | 12.0K | 12.0K | 2.00K | 0 | 1.00K | 4.00K | 4.00K | 1.00K | |
| Income before tax | -90.4M | -75.1M | -36.3M | -55.2M | -60.7M | -33.3M | -69.4M | -31.6M | -50.2M | -37.0M |
| Income tax | 0 | 0 | -16.0K | -5.00K | 17.0K | -1 | 168.1K | -1 | 0 | |
| Net income | -90.4M | -75.1M | -36.3M | -55.2M | -60.7M | -33.3M | -69.4M | -31.6M | -50.2M | -37.0M |
| Earnings per share, basic | -4.24 | -4.28 | -2.83 | -1.04 | -1.10 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 |
| Earnings per share, diluted | -4.24 | -4.28 | -1.04 | -1.10 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 103.8M | 136.6M | 148.2M | 82.0M | 142.5M | 192.6M | 143.1M | 76.9M | 52.0M | 32.3M |
| Short-term investments | 165.2M | 175.8M | 48.9M | 0 | 0 | 56.1M | 70.8M | |||
| Receivables | 648.0K | 600.0K | 990.0K | 790.0K | ||||||
| Inventory | 1.50M | 1.08M | 1.91M | |||||||
| Current assets | 271.8M | 315.9M | 200.3M | 84.7M | 144.0M | 194.5M | 143.6M | 77.2M | 108.8M | 103.5M |
| Property, plant and equipment | 12.8M | 15.4M | 17.2M | 20.1M | 6.45M | 3.57M | 2.06M | 400.0K | 905.0K | 849.0K |
| Total assets | 288.6M | 335.7M | 222.6M | 109.3M | 163.3M | 210.5M | 147.0M | 77.6M | 110.3M | 154.4M |
| Accounts payable | 1.95M | 1.34M | 2.60M | 625.0K | 5.63M | 1.32M | 1.60M | 702.0K | ||
| Current liabilities | 16.4M | 15.2M | 23.0M | 6.65M | 8.64M | 7.89M | 4.74M | 4.63M | 11.0M | 9.52M |
| Total debt | 9.89M | 12.4M | 16.3M | 4.69M | 6.43M | 12.1M | 1.21M | 6.00K | 33.0K | 47.0K |
| Total liabilities | 23.7M | 25.4M | 36.5M | 10.6M | 20.4M | 19.3M | 5.34M | 4.95M | 11.4M | 9.72M |
| Shareholders' equity | 264.9M | 310.4M | 186.0M | -145.7M | -91.9M | 191.2M | 141.7M | 72.7M | 98.9M | 144.7M |
| Shares outstanding | 15.5M | 14.9M | 12.8M | 0 | 42.5M | 42.2M | 38.0M | 23.5M | 23.5M | 23.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -77.2M | -70.6M | -51.4M | -52.8M | -47.6M | -24.6M | -15.4M | -31.6M | -44.7M | -30.2M |
| Capital spending | -1.18M | -808.0K | -321.0K | -2.23M | -3.26M | -2.22M | -879.0K | -49.0K | -494.0K | -713.0K |
| Free cash flow | -78.4M | -71.4M | -51.7M | -55.1M | -50.8M | -26.8M | -16.3M | -31.6M | -45.2M | -30.9M |
| Cash from investing | 14.0M | -125.3M | 25.6M | -2.23M | -3.26M | -2.22M | -688.0K | 56.0M | 64.0M | -48.1M |
| Cash from financing | 30.4M | 184.1M | 92.5M | 66.5M | 732.0K | 77.1M | 82.2M | 570.0K | 423.0K | 71.1M |
| Change in cash | -32.7M | -11.8M | 66.7M | 11.5M | -50.1M | 50.3M | 66.2M | 24.9M | 19.7M | -7.22M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jul 1, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jun 30, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 29, 2026 | Current report | SEC |
| 4/A · Change in ownership, amended | Jun 16, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 16, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 16, 2026 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Jun 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| 8-K · Current report | Jun 4, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 6, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Apr 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 20, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 16, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 24, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 24, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 26, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 8-K · Current report | Nov 6, 2025 | Current report | SEC |
| 8-K · Current report | Oct 9, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Aug 11, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 9, 2025 | Current report | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 14, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 7, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 2, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 1, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 31, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 31, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Mar 24, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 24, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 24, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 24, 2025 | Results | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 18, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 12, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Dec 11, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Dec 9, 2024 | Other filings | SEC |
| S-1 · Registration statement | Dec 2, 2024 | Offer document | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 27, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 27, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 18, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 18, 2024 | Results | SEC |
| 8-K · Current report | Nov 18, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2024 | Explanation request | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 8-K · Current report | Aug 7, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jul 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 21, 2024 | Current report | SEC |
| 8-K · Current report | Jun 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| 8-K · Current report | May 7, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2024 | Management or board change | SEC |
| 8-K · Current report | Apr 22, 2024 | Current report | SEC |
| 8-K · Current report | Apr 2, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 18, 2024 | Results | SEC |
| 10-K · Annual report | Mar 18, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 4, 2024 | Current report | SEC |
| 8-K · Current report | Feb 21, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Feb 20, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 9, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Dec 27, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Dec 26, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 26, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 26, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 26, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 26, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 26, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 22, 2023 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Dec 21, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 20, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 20, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Dec 19, 2023 | Acquisition or disposal | SEC |
| 425 | Dec 6, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 6, 2023 | Current report | SEC |
| 425 | Dec 4, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 4, 2023 | Current report | SEC |
This page holds 200 of 756 filings. Open Filings
Cap table
Built by 6ix from Neurogene Inc.’s releases · as of Nov 5, 2026
- Common shares
- 20,700,905
- Fully diluted
- 20,700,905
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 20,700,905 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 20,700,905 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Felix Baker Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Chairman · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Lead Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Director · Since at least Jan 4, 2008); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Feb 8, 2010 – Jun 19, 2012 · Past); Synageva BioPharma Corp (Director · Aug 14, 2007 – Jun 22, 2015 · Past); Neurogen Corp (Director · Jun 7, 2007 – Jul 25, 2008 · Past); Seagen Inc (Director · May 25, 2007 – Dec 14, 2023 · Past); Genomic Health Inc (Director · May 21, 2007 – Oct 1, 2019 · Past) | Director · May 8, 2017 – Dec 18, 2023 · Past |
| Julian Baker Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 26, 2006 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past) | Director · May 8, 2017 – Dec 18, 2023 · Past |
| Martin Babler Other companies: MapLight Therapeutics, Inc. (Member of the Audit Committee · Since at least Jun 23, 2026); Alumis Inc. (President, Chief Executive Officer and Chairman of the Board · Since at least Jun 27, 2024); 89bio Inc (Director · Since at least Apr 13, 2024); Prelude Therapeutics Incorporated (Director · Since at least Jul 19, 2021); Omega Alpha SPAC (Director · Jan 6, 2021 – Jan 6, 2021 · Past); Principia Biopharma Inc (President, CEO, Director · Sep 13, 2018 – Sep 28, 2020 · Past); ZS Pharma Inc (Director · Mar 19, 2015 – Dec 17, 2015 · Past) | Director · Sep 8, 2020 – Jun 8, 2023 · Past |
| Kelvin Neu Other companies: Theravance Biopharma, Inc. (MD, PhD · Since at least Nov 5, 2026); Zymeworks Inc. (Director · Since at least Mar 16, 2020); Prelude Therapeutics Incorporated (Director · Sep 24, 2020 – Sep 24, 2020 · Past); IGM Biosciences Inc (Director · Sep 17, 2019 – Sep 17, 2019 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Mar 10, 2014 · Past) | Director · Mar 23, 2017 – Mar 23, 2017 · Past |
| Sean P. Nolan Other companies: Taysha Gene Therapies, Inc. (Chief Executive Officer and Board Chairman · Since at least Sep 23, 2020); Ventas, Inc. (Director · Since at least Jul 26, 2019); Social Capital Suvretta Holdings Corp II (Director · Sep 24, 2021 – Sep 24, 2021 · Past); AveXis Inc (President & CEO, Director · Feb 10, 2016 – May 15, 2018 · Past); InterMune Inc (EVP & CBO · Feb 11, 2013 – Sep 29, 2014 · Past) | Director · Feb 16, 2015 – May 5, 2020 · Past |
| Erin Lavelle Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Climb Bio, Inc. (COO & CFO · Aug 9, 2021 – Oct 31, 2022 · Past); Alder BioPharmaceuticals Inc (Chief Operating Officer · Apr 16, 2018 – Oct 22, 2019 · Past) | Director · May 12, 2022 – Jun 8, 2023 · Past |
| Keith Woods Other companies: Scholar Rock Holding Corporation (Chief Operating Officer · Since at least Apr 27, 2025); TScan Therapeutics, Inc. (Director · Since at least Dec 6, 2023); X4 Pharmaceuticals, Inc. (Director · Since at least Oct 16, 2023); Rocket Pharmaceuticals, Inc. (Director · Dec 7, 2023 – Jun 13, 2024 · Past) | Director · Since at least Jun 12, 2025 |
| Lewis T. Rusty Williams Other companies: Protagonist Therapeutics, Inc. (Director, Co-Founder, Chairman · Since at least Jun 7, 2017); Arcellx Inc (Director · Feb 3, 2022 – Feb 8, 2022 · Past); Five Prime Therapeutics Inc (Director · Sep 17, 2013 – Sep 1, 2019 · Past); Beckman Coulter Inc (Director · Oct 23, 2009 – Jun 30, 2011 · Past) | Director · Aug 8, 2019 – May 11, 2021 · Past |
| Christine Mikail Cvijic Other companies: Sio Gene Therapies Inc (Chief Admin Officer and GC · Jun 10, 2015 – Apr 29, 2016 · Past); NPS Pharmaceuticals Inc (SVP, Legal Affairs & GC · Mar 3, 2014 – Feb 21, 2015 · Past); Dendreon Corp (EVP, Corp Dev, Gen Cnsl/Scrtry · Feb 29, 2012 – Feb 10, 2014 · Past) | President and CFO, Director · Since at least Dec 18, 2023 |
| Gary L. Bridger Other companies: X4 Pharmaceuticals, Inc. (Board Member · Since at least Mar 13, 2019); Xenon Pharmaceuticals Inc. (EVP, Research & Development · Nov 4, 2014 – Nov 21, 2014 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 31, 2015 · Past) | Director · Mar 6, 2014 – May 7, 2018 · Past |
All 42 people
| Person | Seat |
|---|---|
| Jonathan G Drachman Other companies: Harpoon Therapeutics Inc (Director · Feb 7, 2019 – Mar 8, 2024 · Past); Calithera Biosciences, Inc. (Director · Oct 1, 2014 – Nov 10, 2021 · Past); Seagen Inc (CMO & EVP, R & D · Oct 1, 2013 – Mar 20, 2018 · Past) | President and CEO, Director · Aug 8, 2019 – Aug 2, 2022 · Past |
| Robert A. Baffi Other companies: Mosaic ImmunoEngineering Inc (Director · Since at least Jul 15, 2021); Humanigen Inc (Director · Nov 25, 2014 – Jul 10, 2015 · Past); BioMarin Pharmaceutical Inc. (President, Global Mfg/Tech Ops · Apr 10, 2013 – Mar 20, 2020 · Past) | Director · Since at least Dec 18, 2023 |
| Rohan Palekar Other companies: 89bio Inc (Chief Executive Officer, Director · Since at least Nov 8, 2019); Avanir Pharmaceuticals Inc (SVP & Chief Commercial Officer · Apr 3, 2012 – Nov 28, 2014 · Past); Medivation Inc (Chief Commercial Officer · Jan 14, 2008 – Apr 20, 2011 · Past) | Director · Since at least Mar 2, 2022 |
| Sarah B. Noonberg Other companies: Metagenomi Therapeutics, Inc. (Chief Medical Officer · Since at least Feb 8, 2024); Marinus Pharmaceuticals Inc (Director · May 16, 2023 – Jun 18, 2024 · Past); Protagonist Therapeutics, Inc. (Director · Dec 12, 2017 – Jan 16, 2023 · Past) | Director · Since at least Aug 8, 2019 |
| Kamran Alam Other companies: Taysha Gene Therapies, Inc. (Chief Financial Officer · Since at least Sep 23, 2020); Rocket Pharmaceuticals, Inc. (SVP - Finance & PFO · Oct 28, 2019 – Feb 6, 2020 · Past) | CFO, Vice President Finance · Mar 9, 2018 – Aug 7, 2018 · Past |
| Todd Simpson Other companies: Xencor, Inc. (Director · Since at least Mar 13, 2025); Seagen Inc (Chief Financial Officer · Jan 31, 2006 – Dec 14, 2023 · Past) | Director · Mar 6, 2014 – Jun 8, 2023 · Past |
| Christina Shafer Other companies: Marinus Pharmaceuticals Inc (CHIEF COMMERCIAL OFFICER · Jun 15, 2022 – Feb 7, 2025 · Past) | Chief Commercial Officer · Since at least Apr 20, 2026 |
| Cory S Freedland Other companies: Jiya Acquisition Corp (Chief Investment Officer, Director · Nov 18, 2020 – Nov 18, 2020 · Past) | Director · Since at least Dec 18, 2023 |
| Daniel J Levitt Other companies: Sorrento Therapeutics, Inc. (Director · Jan 30, 2014 – Jan 30, 2014 · Past) | Director · Mar 6, 2014 – May 14, 2018 · Past |
| Julie Jordan Other companies: Q32 Bio Inc. (Chief Medical Officer · Mar 7, 2023 – Aug 3, 2023 · Past) | Chief Medical Officer · Since at least Jan 16, 2024 |
| Meta Cantey Boyd Other companies: Kiniksa Pharmaceuticals International, plc (Director · Oct 4, 2024 – Oct 4, 2024 · Past) | Director · Aug 8, 2019 – Aug 8, 2019 · Past |
| Rachel McMinn Other companies: Intercept Pharmaceuticals Inc (Chief Strategy Officer · Apr 30, 2014 – Oct 2, 2017 · Past) | Founder and Chief Executive Officer · Since at least Dec 18, 2023 |
| Robert Ho Other companies: Third Harmonic Bio Inc. (Chief Financial Officer · Sep 14, 2022 – Mar 6, 2023 · Past) | Chief Financial Officer · Mar 16, 2020 – Feb 1, 2022 · Past |
| Shelley McCloskey Other companies: Xenon Pharmaceuticals Inc. (Executive Vice President, Human Resources · Since at least Nov 5, 2026) | VP, HR and Administration · Dec 14, 2015 – Aug 7, 2018 · Past |
| Abigail Jenkins | Chief Commercial Officer · Jun 6, 2016 – Mar 9, 2018 · Past |
| Andrew Mulberg | Senior Vice President, Regulatory Affairs, Quality Assurance, and Quality Control · Since at least Nov 4, 2026 |
| Arvind Sreedharan | Senior Vice President, Business Operations · Since at least Nov 5, 2026 |
| Carl Walkey | Senior Vice President · Jan 30, 2021 – Aug 2, 2022 · Past |
| Christine Mikail | President and Chief Financial Officer · Since at least Apr 20, 2026 |
| Christy Shafer | Chief Commercial Officer · Since at least Apr 20, 2026 |
| David Chilton Mitchell | VP Global Regulatory & Quality · Aug 11, 2015 – Mar 8, 2017 · Past |
| David Main | President and CEO, Director · Mar 6, 2014 – Aug 7, 2018 · Past |
| Donna M. Cochener | Senior Vice President and General Counsel · Since at least Mar 14, 2022 |
| Erin M Lavelle | Director · Jun 1, 2020 – May 11, 2021 · Past |
| Holly Vance | General Counsel · Oct 19, 2020 – Aug 3, 2021 · Past |
| Lina Li | Executive Director, Investor Relations · Since at least Sep 8, 2026 |
| Mike Devine | Executive Director, Corporate Communications · Since at least Sep 8, 2026 |
| Priti Patel | Chief Medical Officer · Apr 30, 2021 – Feb 1, 2023 · Past |
| Ricardo Jimenez | Senior Vice President, Technical Operations · Since at least Nov 5, 2026 |
| Robert Keith Woods | Director · Since at least Dec 18, 2023 |
| Sean Michael Smith | Interim CFO, Prin Acct Off · Mar 2, 2022 – Aug 10, 2023 · Past |
| Stuart Cobb | Chief Scientific Officer · Since at least Dec 18, 2023 |
Log in to ask 6ix AI your own questions about Neurogene Inc.